{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:14:21Z","timestamp":1777436061974,"version":"3.51.4"},"reference-count":25,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT"],"published-print":{"date-parts":[[2008]]},"DOI":"10.5551\/jat.e567","type":"journal-article","created":{"date-parts":[[2011,6,16]],"date-time":"2011-06-16T13:45:38Z","timestamp":1308231938000},"page":"314-323","source":"Crossref","is-referenced-by-count":28,"title":["Superior Benefit of Aggressive Lipid-Lowering Therapy for High- Risk Patients Using Statins: the SUBARU Study -More Hypercholesterolemic Patients Achieve Japan Atherosclerosis Society LDL-C Goals with Rosuvastatin Therapy than with Atorvastatin Therapy"],"prefix":"10.5551","volume":"15","author":[{"given":"Masahiko","family":"Kurabayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"SUBARU Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Kannel WB, Castelli WP, Gordon T: Cholesterol in the prediction of atherosclerotic disease: New perspectives based on the Framingham study. Ann Intern Med, 1979; 90: 85-91","DOI":"10.7326\/0003-4819-90-1-85"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92521-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, and Braunwald E: The effect of prava-statin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med, 1996; 335: 1001-1009","DOI":"10.1056\/NEJM199610033351401"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998; 339: 1349-1357","DOI":"10.1056\/NEJM199811053391902"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Shepherd J, Cobbe M, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333: 1301-1307","DOI":"10.1056\/NEJM199511163332001"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.20.1615"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.278.4.313"},{"key":"8","unstructured":"8) Japan Atherosclerosis Society: Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2005.04.004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol, 2003; 92: 152-160","DOI":"10.1016\/S0002-9149(03)00530-7"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01727-1"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M: Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J, 2004; 148: e4","DOI":"10.1016\/j.ahj.2004.01.020"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.10.004"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.5.499"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.5551\/jat.14.45"},{"key":"16","unstructured":"16) Third Report of the NCEP Expert Panel: NIH Publication No. 01-3670 2001. http:\/\/hin.nhlbi.nih.gov\/ncep_ slds\/menu.htm"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.5551\/jat.10.329"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.5551\/jat.11.152"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.11.028"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.5.2.161"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.jpc60002"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.12.1344"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706201"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1278"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1281"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T18:46:24Z","timestamp":1621536384000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jat\/15\/6\/15_E567\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.e567","relation":{},"ISSN":["1880-3873","1340-3478"],"issn-type":[{"value":"1880-3873","type":"electronic"},{"value":"1340-3478","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}